Tidal Investments LLC Grows Position in Zoetis Inc. $ZTS

Tidal Investments LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 22.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 493,507 shares of the company’s stock after purchasing an additional 91,492 shares during the period. Tidal Investments LLC’s holdings in Zoetis were worth $35,463,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Brighton Jones LLC increased its position in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC increased its holdings in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC raised its position in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares during the period. Finally, Glenview Trust co grew its position in shares of Zoetis by 11.8% in the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on ZTS shares. Piper Sandler dropped their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday, August 25th. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $101.08.

Zoetis Price Performance

ZTS opened at $73.39 on Thursday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.33 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 1.72 and a beta of 0.73. The stock has a fifty day simple moving average of $75.63 and a two-hundred day simple moving average of $92.49. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $152.00.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.